1
|
Nakajima-Kato Y, Komai M, Yoshida T, Kanai A. A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose. Clin Exp Immunol 2023; 211:23-30. [PMID: 36480334 PMCID: PMC9993454 DOI: 10.1093/cei/uxac112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 11/04/2022] [Accepted: 12/06/2022] [Indexed: 12/13/2022] Open
Abstract
Intravenous immunoglobulin (IVIG) is a well-established treatment for various autoimmune and inflammatory diseases. However, the standard dose prescribed for autoimmune diseases, including immune thrombocytopenic purpura (ITP), is 2 g/kg, which is markedly high and leads to a high treatment burden. In this study, we generated fragment crystallizable (Fc)-modified anti-haptoglobin (Hp) monoclonal antibodies with non-inferior efficacy compared to IVIG at considerably lower doses than IVIG, as shown by in vitro experiments. We evaluated binding activity of anti-Hp antibodies to Fc gamma receptors (FcγRs) with ELISA and inhibitory activity against the ADCC reaction. Furthermore, we successfully established a novel cynomolgus monkey ITP model and demonstrated that the anti-Hp antibody exerted its effect in this model with only a single dose. This Fc-modified anti-Hp monoclonal antibody could be a valuable therapeutic replacement for IVIG for the treatment of ITP.
Collapse
Affiliation(s)
- Yuko Nakajima-Kato
- Correspondence: Yuko Nakajima-Kato, Biomedical Science Research Laboratories 2, Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Japan
| | - Masato Komai
- Biomedical Science Research Laboratories 2, Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Japan
| | - Tadashi Yoshida
- Graduate School of Bio-Applications and Systems Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan
- Department of Applied Biological Science, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Akiko Kanai
- Biomedical Science Research Laboratories 1, Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Japan
| |
Collapse
|
2
|
Ho SL, Xu D, Wong MS, Li HW. Direct and multiplex quantification of protein biomarkers in serum samples using an immuno-magnetic platform. Chem Sci 2016; 7:2695-2700. [PMID: 28660042 PMCID: PMC5477028 DOI: 10.1039/c5sc04115e] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 12/26/2015] [Indexed: 12/21/2022] Open
Abstract
A direct and ultrasensitive multiplex assay using an immuno-magnetic platform has been developed for the quantification of trace amounts of circulating cancer-associated antigens in serum.
A direct and ultrasensitive multiplex assay using an immuno-magnetic platform has been developed for the quantification of trace amounts of circulating cancer-associated antigens in serum. The detection is based on the specific immuno-interactions among the target antigen, detection antibody and capture antibody that is immobilized on the surface of magnetic nanoparticles. The sandwiched immuno-assembly is then labelled with turn-on fluorophores and detected with a fluorescence imaging system. To afford a high signal-to-noise ratio, three turn-on fluorophores with unique optical properties have been designed and synthesized to label the target antigens. The developed assay has achieved a remarkable LOD down to the femto-molar regime without sample pre-treatment. This versatile assay can efficiently differentiate the target antigen from a protein matrix and simultaneously quantify multiple cancer-associated antigens, for instance, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and prostate specific antigen (PSA) using only 6 μL of serum sample in an hour. This novel system has a high applicability to serve as a universal and useful tool for early disease diagnostics.
Collapse
Affiliation(s)
- See-Lok Ho
- Department of Chemistry , Hong Kong Baptist University , Hong Kong . ;
| | - Di Xu
- Department of Chemistry , Hong Kong Baptist University , Hong Kong . ;
| | - Man Shing Wong
- Department of Chemistry , Hong Kong Baptist University , Hong Kong . ;
| | - Hung-Wing Li
- Department of Chemistry , Hong Kong Baptist University , Hong Kong . ;
| |
Collapse
|
3
|
Tremblay T, Paré I, Bazin R. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia. Transfusion 2012; 53:261-9. [DOI: 10.1111/j.1537-2995.2012.03725.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
4
|
Shashidharamurthy R, Zhang F, Amano A, Kamat A, Panchanathan R, Ezekwudo D, Zhu C, Selvaraj P. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. THE JOURNAL OF IMMUNOLOGY 2010; 183:8216-24. [PMID: 20007585 DOI: 10.4049/jimmunol.0902550] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CD32A, the major phagocytic FcgammaR in humans, exhibits a polymorphism in the ligand binding domain. Individuals homozygous for the R allelic form of CD32A (CD32A(R) allele) are more susceptible to bacterial infections and autoimmune diseases as compared with H allelic CD32A (CD32A(H)) homozygous and CD32A(R/H) heterozygous individuals. To understand the mechanisms behind this differential susceptibility, we have investigated the dynamics of the interaction of these allelic forms of CD32A when they are simultaneously exposed to immune complexes (IC). Binding studies using Ig fusion proteins of CD32A alleles showed that the R allele has significantly lower binding not only to human IgG2, but also to IgG1 and IgG3 subtypes. Competition assays using purified molecules demonstrated that CD32A(H)-Ig outcompetes CD32A(R)-Ig for IC binding when both alleles simultaneously compete for the same ligand. CD32A(H)-Ig blocked the IC binding mediated by both the allelic forms of cell surface CD32A, whereas CD32A(R)-Ig blocked only CD32A(R) and was unable to cross-block IC binding mediated by CD32A(H). Two-dimensional affinity measurements also demonstrated that CD32A(R) has significantly lower affinity toward all three subtypes as compared with CD32A(H). Our data suggest that the lower binding of CD32A(R) not only to IgG2 but also to IgG1 and IgG3 might be responsible for the lack of clearance of IC leading to increased susceptibility to bacterial infections and autoimmune diseases. Our data further suggests that in humans, inflammatory cells from CD32A(R/H) heterozygous individuals may predominantly use the H allele to mediate Ab-coated target cell binding during phagocytosis and Ab-dependent cellular cytotoxicity, resulting in a phenotype similar to CD32A(H) homozygous individuals.
Collapse
|
5
|
Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2009; 98:12-28. [PMID: 19660029 DOI: 10.1111/j.1423-0410.2009.01226.x] [Citation(s) in RCA: 119] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.
Collapse
|
6
|
Polyreactive antibodies in multidonor-derived immunoglobulin G: theory and conclusions drawn from experiments. Immunobiology 2009; 215:356-69. [PMID: 19592128 DOI: 10.1016/j.imbio.2009.06.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2009] [Revised: 06/05/2009] [Accepted: 06/10/2009] [Indexed: 11/21/2022]
Abstract
Multidonor-derived (md) preparations of IgG antibodies, agents of therapeutic potential, contain molecules interacting at clonal concentrations (concns) and with affinities recently estimated to cover a considerable range. Here we demonstrate that polyreactivity of the monomeric molecules represents the essential driving force of formation of the main reaction product, the IgG-dimers. This conclusion is obtained by applying the principles of the law of mass action to dimer formation by polyreactive monomeric reactants. In addition, general interrelationships involving the mean number of reactants per reactor, the experimental dimer portion (w/w) and the mean concentrations of monomers in a polyreactive and monoreactive antibody system are derived. These interrelationships, together with quantitative results obtained from simplified computational kinetic models of polyreactive antibodies, allow to estimate a remarkably high value for the mean number of reactants per reactor, exceeding 60 for the underlying IgG preparation obtained from pooled human plasma units of 5000 donors. Moreover, the potential origin and other consequences of polyreactivity are outlined.
Collapse
|
7
|
Proulx DP, Aubin É, Lemieux R, Bazin R. Spontaneous internalization of IVIg in activated B cells. Immunol Lett 2009; 124:18-26. [DOI: 10.1016/j.imlet.2009.03.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2009] [Revised: 03/17/2009] [Accepted: 03/26/2009] [Indexed: 01/06/2023]
|
8
|
García-Muñoz R. Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations. Clin Rheumatol 2008; 28:361-3. [PMID: 19093141 DOI: 10.1007/s10067-008-1065-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2008] [Revised: 11/16/2008] [Accepted: 11/19/2008] [Indexed: 11/26/2022]
|
9
|
Di Giambattista M, Branckaert T, Hougardy V, Kemball-Cook G, Laub R. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates. Mol Immunol 2006; 44:1903-13. [PMID: 17113150 DOI: 10.1016/j.molimm.2006.09.034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2006] [Accepted: 09/29/2006] [Indexed: 11/15/2022]
Abstract
Inhibitory antibodies directed against blood coagulation factor VIII (FVIII) impair FVIII replacement therapy, constituting a serious complication in haemophilic and autoimmune patients. Identifying B-cell FVIII epitopes and mapping them on the molecule remain important challenges. Using a combination of different algorithms, more than 30 hypothetical linear epitopes were predicted on the FVIII molecule surface. We selected several major predicted sequences, spanning all FVIII domains, for specific antibody induction in rabbits. All peptides tested successfully induced production of specific anti-FVIII rabbit antibodies, supporting the relevance of our approach. To investigate the presence of FVIII-reactive antibodies in the healthy donor population, a pooled fraction rich in all IgG subclasses was purified on peptide-Sepharose columns. Substantial amounts of Ig, specific for each FVIII peptide, were purified with yields ranging from 8 to 223 ng/mg immunoglobulins. Our results confirm the diversity of FVIII epitopes recognised by natural human anti-FVIII autoantibodies. All IgG subclasses were found in the affinity-isolated anti-peptide material, with overrepresentation of IgG2 and IgG4. Evidence was also found for new FVIII epitopes. Five human anti-peptide preparations displayed FVIII-neutralising activity, ranging from 1.3 to 5.3 BU/mg. Although the presence of naturally occurring anti-FVIII antibodies in healthy donors has been previously described, our methodology has allowed, for the first time, a fine mapping of several inhibitory and non-inhibitory epitopes. Our observations support the hypothesis that FVIII inhibitors in haemophilia A and autoimmune disease may originate from the proliferation of natural FVIII-specific B-cell clones.
Collapse
Affiliation(s)
- Mario Di Giambattista
- Research & Development Unit, Central Department for Fractionation, Avenue de Tyras 109, Red Cross, B-1120 Brussels, Belgium
| | | | | | | | | |
Collapse
|
10
|
van de Velde NC, Mottram PL, Hogarth PM. FcgammaRII and multi-system autoimmune disease. ACTA ACUST UNITED AC 2006; 28:329-38. [PMID: 17091247 DOI: 10.1007/s00281-006-0056-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Accepted: 10/11/2006] [Indexed: 12/20/2022]
Abstract
The FcR are a crucial link in the immune response between humoral and cellular immunity and cell-based effector systems, mediating a wide variety of physiological and biochemical responses. The FcR for IgG (FcgammaR) and in particular the most widely expressed of these, FcgammaRII, are important in regulating adaptive immunity. Disruption of their function is a key factor in the development of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), which are characterized by chronic, multi-organ inflammation. Studies of the FcgammaRII include structure/function relationships, investigation of the associations between FcR polymorphisms and human disease and animal studies using knockout or transgenic mouse models. These investigations showed that the various forms of FcgammaRII interact with immune complexes to either initiate or inhibit inflammation. In conjunction with environmental antigens and genotype, the FcgammaRII activating and inhibitory receptors determine the nature and magnitude of response to antigens. In this review, the structure and function of the FcgammaRIIs and their role in immune complex-mediated auto-immunity are discussed.
Collapse
Affiliation(s)
- Nicholas C van de Velde
- Burnet Institute (Austin Campus), Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia,
| | | | | |
Collapse
|
11
|
Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135:97-100. [PMID: 16925577 DOI: 10.1111/j.1365-2141.2006.06245.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Intravenous immunoglobulins (IVIgs) are used to treat an increasing number of autoimmune diseases, but their exact mechanism of action remains unknown. This study showed that cross-linking of human IgG present in IVIg preparations using a mouse monoclonal anti-human IgG generated complexes that prevented or reversed thrombocytopenia in mice more efficiently than IVIg. Furthermore, biologically active complexes were obtained simply by adding the monoclonal antibody to human serum. These results suggest the possible development of an IVIg-free substitute through the ex vivo, and possibly in vivo, formation of immune complexes containing autologous IgG of immune thrombocytopenic purpura patients.
Collapse
Affiliation(s)
- Renée Bazin
- Department of Research and Development, Héma-Québec, Quebec, QC, Canada.
| | | | | |
Collapse
|